Is Regulus Therapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 4 Wall Street analysts covering (NASDAQ: RGLS) stock is to Buy RGLS stock.
Out of 4 analysts, 1 (25%) are recommending RGLS as a Strong Buy, 2 (50%) are recommending RGLS as a Buy, 1 (25%) are recommending RGLS as a Hold, 0 (0%) are recommending RGLS as a Sell, and 0 (0%) are recommending RGLS as a Strong Sell.
According to 4 Wall Street analysts that have issued a 1 year RGLS price target, the average RGLS price target is $7.25, with the highest RGLS stock price forecast at $11.00 and the lowest RGLS stock price forecast at $3.00.
On average, Wall Street analysts predict that Regulus Therapeutics's share price could reach $7.25 by Mar 25, 2025. The average Regulus Therapeutics stock price prediction forecasts a potential upside of 151.74% from the current RGLS share price of $2.88.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.